Use of a controlled attenuation parameter for the diagnosis of non-alcoholic fatty liver disease

被引:0
|
作者
Goncharov, Alexey A. [1 ]
Sasunova, Armida N. [1 ]
Pilipenko, Vladimir I. [1 ]
Isakov, Vasily A. [1 ]
机构
[1] Fed Res Ctr Nutr Biotechnol & Food Safety, Moscow, Russia
来源
TERAPEVTICHESKII ARKHIV | 2023年 / 95卷 / 08期
关键词
CAP; non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; VCTE; ACCURACY;
D O I
10.26442/00403660.2023.08.202348
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. To evaluate the efficacy of vibration-controlled transient elastography (VCTE) with a controlled attenuation parameter (CAP) in a population of patients with non-alcoholic fatty liver disease (NAFLD)and to compare to US and different non-invasive indices. Materials and methods. Single center NAFLD patients' database of 2021-2023 years was retrospectively analysed. Data of VCTE evaluation with CAP (FibroScan 530((R)) and FibroScan 630 Expert((R))) as well as liver US examination results and values of HSI, FLI, BAAT and NAFLD-LFS were extracted. AUROCs for all methods used were constructed and sensitivity and specificity analysis was performed. Results. The data of 1081 patients were available for analysis (385 with steatosis, 274 with NASH, 422 without NAFLD as a control). Ultrasound examination in the diagnosis of liver steatosis compared to VCTE with CAP showed sensitivity and specificity of 94.6 and 63.7%, respectively. Diagnosis of liver steatosis using indices and scales showed sensitivity and specificity of HSI: 97.9 and 60.1% (AUROC 0.90), FLI: 92.5 and 85.3% (AUROC 0.93), BAAT: 76.6 and 73.5% (AUROC 0.82), NAFLD-LFS: 56.7 and 81.8% (AUROC 0.85). Conclusion. The sensitivity of the US of the liver was consistent with previous studies, but the specificity was low. The HSI index had the best indicators of sensitivity and specificity in relation to the diagnosis of liver steatosis. Combination of liver US and HSI can be used in screening of liver steatosis, however, for the complete diagnosis better tools which can simultaneously evaluate liver steatosis and fibrosis should be used.
引用
收藏
页码:641 / 647
页数:7
相关论文
共 50 条
  • [41] Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease
    Marzuillo, Pierluigi
    Grandone, Anna
    Perrone, Laura
    del Giudice, Emanuele Miraglia
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (21) : 6444 - 6450
  • [43] Metabolomic Biomarkers in the Diagnosis of Non-Alcoholic Fatty Liver Disease
    Chashmniam, Saeed
    Ghafourpour, Mohsen
    Farimani, Azam Rezaei
    Gholami, Ali
    Ghoochani, Bibi Fatemeh Nobakht Motlagh
    [J]. HEPATITIS MONTHLY, 2019, 19 (09)
  • [44] Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease
    Pierluigi Marzuillo
    Anna Grandone
    Laura Perrone
    Emanuele Miraglia del Giudice
    [J]. World Journal of Gastroenterology, 2015, (21) : 6444 - 6450
  • [45] Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
    Tincopa, Monica A.
    Loomba, Rohit
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (07): : 660 - 670
  • [46] Non-alcoholic Fatty Liver Disease Diagnosis and Therapy of NAFLD
    Canbay, Ali
    Lammert, Frank
    Geier, Andreas
    [J]. INTERNIST, 2021, 62 (05): : 485 - 485
  • [47] Non-alcoholic fatty liver disease
    Angulo, P
    Lindor, KD
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2002, 17 : S186 - S190
  • [48] Non-alcoholic Fatty Liver Disease
    Tan, Hui-Hui
    Chang, Jason Pik-Eu
    [J]. PROCEEDINGS OF SINGAPORE HEALTHCARE, 2010, 19 (01) : 36 - 50
  • [49] Non-alcoholic fatty liver disease
    Powell, Elizabeth E.
    Wong, Vincent Wai-Sun
    Rinella, Mary
    [J]. LANCET, 2021, 397 (10290): : 2212 - 2224
  • [50] Non-alcoholic fatty liver disease
    Neuschwander-Tetri, Brent A.
    [J]. BMC MEDICINE, 2017, 15